EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.

Summary Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-related death globally. Hepatocellular carcinoma represents about 90% of primary liver cancers and constitutes a major global health problem. The following Clinical Practice Guidelines will give up-to-date advice for the clinical management of patients with hepatocellular carcinoma, as well as providing an in-depth review of all the relevant data leading to the conclusions herein.

• Publication year

  2018

• Venue

  Journal of Hepatology

• Publication date

  2018-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jhep.2018.03.019PMID 29628281
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Distinguishing intrahepatic cholangiocarcinoma from hepatocellular carcinoma in patients with and without risks: the evaluation of the LR-M criteria of contrast-enhanced ultrasound liver imaging reporting and data system version 2017

  2019cited by this paper
• A randomized placebo‐controlled trial of prophylactic dexamethasone for transcatheter arterial chemoembolization

  2018cited by this paper
• Hepatocellular carcinoma

  2018cited by this paper
• Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial.

  2018influential reference
• Macrotrabecular‐massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance

  2018cited by this paper
• Pro (With Caution): Extended oncologic indications in liver transplantation

  2018cited by this paper
• SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma.

  2018cited by this paper
• Invited Editorial: The Southampton Consensus Guidelines for Laparoscopic Liver Surgery: From Innovation to Implementation.

  2018cited by this paper
• KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.

  2018cited by this paper
• Individualized Adaptive Stereotactic Body Radiotherapy for Liver Tumors in Patients at High Risk for Liver Damage: A Phase 2 Clinical Trial

  2018cited by this paper
• EASL Recommendations on Treatment of Hepatitis C 2018.

  2018cited by this paper
• Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.

  2018cited by this paper
• AASLD guidelines for the treatment of hepatocellular carcinoma

  2018cited by this paper
• Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.

  2018cited by this paper
• Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma.

  2018cited by this paper
• Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.

  2018cited by this paper
• OPTN/SRTR 2015 Annual Data Report: Liver

  2017cited by this paper
• Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection

  2017cited by this paper
• Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct‐acting antivirals? A prospective multicentre study

  2017cited by this paper
• High-dose radiotherapy is associated with better local control of bone metastasis from hepatocellular carcinoma

  2017cited by this paper
• Stereotactic body radiotherapy for patients with hepatocellular carcinoma and intermediate grade cirrhosis.

  2017cited by this paper
• Hepatocellular adenoma: Classification, variants and clinical relevance.

  2017cited by this paper
• Liver and biliary damages following transarterial chemoembolization of hepatocellular carcinoma: comparison between drug-eluting beads and lipiodol emulsion

  2017cited by this paper
• Randomized clinical trial of hepatic resection versus radiofrequency ablation for early‐stage hepatocellular carcinoma

  2017cited by this paper
• Evaluation of Early Allograft Function Using the Liver Graft Assessment Following Transplantation Risk Score Model

  2017cited by this paper
• EASL Recommendations on Treatment of Hepatitis C 2016.

  2017cited by this paper
• Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.

  2017cited by this paper
• Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon

  2017cited by this paper
• Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification.

  2017cited by this paper
• Coffee and the risk of hepatocellular carcinoma and chronic liver disease: a systematic review and meta-analysis of prospective studies

  2017influential reference
• The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B

  2017cited by this paper
• Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012.

  2017cited by this paper
• Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis.

  2017cited by this paper
• Influence of Metabolic Risk Factors on Risk of Hepatocellular Carcinoma and Liver-Related Death in Men With Chronic Hepatitis B: A Large Cohort Study.

  2017cited by this paper
• Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.

  2017cited by this paper
• Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel.

  2017cited by this paper
• Muscle volume loss as a prognostic marker in hepatocellular carcinoma patients treated with sorafenib

  2017cited by this paper
• Gadoxetic acid‐enhanced MRI for the characterization of hepatocellular carcinoma: A systematic review and meta‐analysis

  2017cited by this paper
• Sorafenib in Patients with Hepatocellular Carcinoma—Results of the Observational INSIGHT Study

  2017cited by this paper
• Liver Transplantation After Transarterial Chemoembolization and Radiotherapy for Hepatocellular Carcinoma with Vascular Invasion

  2017cited by this paper
• Reduction in liver transplant wait‐listing in the era of direct‐acting antiviral therapy

  2017cited by this paper
• Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical review

  2017cited by this paper
• The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma.

  2017cited by this paper
• Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.

  2017cited by this paper
• Radiotherapeutic strategies for hepatocellular carcinoma with portal vein tumour thrombosis in a hepatitis B endemic area

  2017cited by this paper
• Macrovascular invasion is not an absolute contraindication for living donor liver transplantation

  2017cited by this paper
• Extended Oncologic Indications in Liver Transplantation: PRO (with caution).

  2017cited by this paper
• Predictive Value of 18F-FDG PET/CT for Vascular Invasion in Patients With Hepatocellular Carcinoma Before Liver Transplantation

  2017cited by this paper
• Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.

  2017influential reference
• The ART-SCORE is not an effective tool for optimizing patient selection for DEB-TACE retreatment. A multicentre Spanish study.

  2017cited by this paper
• Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules.

  2017cited by this paper
• Proposal of a novel MELD exception point system for hepatocellular carcinoma based on tumor characteristics and dynamics.

  2017cited by this paper
• Validation of the Hong Kong Liver Cancer Staging System in Determining Prognosis of the North American Patients Following Intra‐arterial Therapy

  2017cited by this paper
• The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level

  2017cited by this paper
• Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression.

  2017cited by this paper
• Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.

  2017cited by this paper
• Liver Cancer Emergence Associated with Antiviral Treatment: An Immune Surveillance Failure?

  2017cited by this paper
• Outcome of All-Oral Direct-Acting Antiviral Regimens on the Rate of Development of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Genotype 1-Related Chronic Liver Disease

  2017cited by this paper
• Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches

  2017cited by this paper
• Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study

  2017cited by this paper
• External radiation or ablation for solitary hepatocellular carcinoma: A survival analysis of the SEER database

  2017cited by this paper
• EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.

  2017cited by this paper
• Second-line tivantinib (ARQ 197) vs placebo in patients (Pts) with MET-high hepatocellular carcinoma (HCC): Results of the METIV-HCC phase III trial.

  2017cited by this paper
• Molecular predictors of recurrence prevention with sorafenib as adjuvant therapy in hepatocellular carcinoma: Biomarker study of the STORM phase III trial

  2017cited by this paper
• The possibility of radiotherapy as downstaging to living donor liver transplantation for hepatocellular carcinoma with portal vein tumor thrombus

  2017cited by this paper
• The Southampton Consensus Guidelines for Laparoscopic Liver Surgery: From Indication to Implementation

  2017cited by this paper
• Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.

  2017cited by this paper
• Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: A Japanese nationwide survey

  2017cited by this paper
• Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC.

  2017cited by this paper
• Early Detection of Hepatocellular Carcinoma After Treatment With Direct-Acting Antivirals: Selection Bias or Biologically Plausible?

  2017cited by this paper
• Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis.

  2017cited by this paper
• External beam radiotherapy for unresectable hepatocellular carcinoma.

  2017cited by this paper
• Non-invasive diagnosis of hepatocellular carcinoma revisited

  2017cited by this paper
• American College of Radiology Contrast Enhanced Ultrasound Liver Imaging Reporting and Data System (CEUS LI-RADS) for the diagnosis of Hepatocellular Carcinoma: a pictorial essay

  2017cited by this paper
• Locoregional Therapy With Curative Intent Versus Primary Liver Transplant for Hepatocellular Carcinoma: Systematic Review and Meta-Analysis

  2017cited by this paper
• EASL and AASLD recommendations for the diagnosis of HCC to the test of daily practice

  2017influential reference
• Intrahepatic Cholangiocarcinoma in Patients with Cirrhosis: Differentiation from Hepatocellular Carcinoma by Using Gadoxetic Acid-enhanced MR Imaging and Dynamic CT.

  2017cited by this paper
• mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib

  2017cited by this paper
• Management of people with early- or very early-stage hepatocellular carcinoma: an attempted network meta-analysis.

  2017cited by this paper
• Safety and Efficacy of Irreversible Electroporation for the Treatment of Hepatocellular Carcinoma Not Amenable to Thermal Ablation Techniques: A Retrospective Single-Center Case Series.

  2017cited by this paper
• Diagnosis of Hepatocellular Carcinoma with Non-Invasive Imaging: a Plea for Worldwide Adoption of Standard and Precise Terminology for Describing Enhancement Criteria

  2017cited by this paper
• Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents.

  2017influential reference
• Proliferation Markers Are Associated with MET Expression in Hepatocellular Carcinoma and Predict Tivantinib Sensitivity In Vitro

  2017cited by this paper
• Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus–infected patients treated with direct‐acting antivirals

  2017cited by this paper
• Contrast enhanced ultrasound identifies hepatocellular carcinoma in cirrhosis: a large multicenter retrospective study

  2017cited by this paper
• Living donor liver transplantation for hepatocellular carcinoma in Seoul National University.

  2016cited by this paper
• Efficacy and Safety of Radiofrequency Ablation Combined with Transcatheter Arterial Chemoembolization for Hepatocellular Carcinomas Compared with Radiofrequency Ablation Alone: A Time-to-Event Meta-Analysis

  2016cited by this paper
• Diagnostic value of combining 11C-choline and 18F-FDG PET/CT in hepatocellular carcinoma

  2016cited by this paper
• Four‐year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients

  2016cited by this paper
• Safety of the Gadolinium-Based Contrast Agents for Magnetic Resonance Imaging, Focusing in Part on Their Accumulation in the Brain and Especially the Dentate Nucleus

  2016cited by this paper
• Trends in the Burden of Nonalcoholic Fatty Liver Disease in a United States Cohort of Veterans.

  2016cited by this paper
• Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone.

  2016cited by this paper
• Squaring the circle of selection and allocation in liver transplantation for HCC: An adaptive approach

  2016cited by this paper
• Accepted Manuscript Long-Term Effects of Hepatitis B Immunization of Infants in Preventing Liver Cancer

  2016cited by this paper
• Diagnostic performance of contrast-enhanced multidetector computed tomography and gadoxetic acid disodium-enhanced magnetic resonance imaging in detecting hepatocellular carcinoma: direct comparison and a meta-analysis

  2016cited by this paper
• Microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma: A systematic review and meta-analysis

  2016influential reference
• A predictive model for carcinogenesis in patients with chronic hepatitis B undergoing entecavir therapy and its validation

  2016cited by this paper
• Radiofrequency ablation of hepatocellular carcinoma: Mono or multipolar?

  2016cited by this paper
• Prediction of posthepatectomy liver failure based on liver stiffness measurement in patients with hepatocellular carcinoma.

  2016cited by this paper
• Erratum: Predicting Liver-Related Events Using Transient Elastography in Chronic Hepatitis C Patients with Sustained Virological Response

  2016cited by this paper

• Identifying Sorafenib Benefit among Hepatocellular Carcinoma Patients: A Transcriptomic and Genomic Approach

  2026cites this paper
• Lipiodol-Mediated Dose Enhancement in Radiation Therapy: A Phantom and In Vitro Study in Hepatocellular Carcinoma.

  2026cites this paper
• Prospective evaluation of liver cancer volumes on non-contrast 1.5 T MR Linac imaging

  2026cites this paper
• Impact of Prior Treatment History on Recurrence After Complete Response to Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma

  2026cites this paper
• Long-term worst outcomes of baseline grey-zone patients with HBeAg-negative chronic hepatitis B virus infection

  2026cites this paper
• Baseline CT imaging features combined with clinical indicators predict prognosis in unresectable HCC treated with HAIC plus targeted therapy and immunotherapy.

  2026cites this paper
• Segmental versus subsegmental transarterial chemoembolization (TACE) for small (< 3 cm) hepatocellular carcinoma (HCC): Less selective, more effective? A propensity score-matched analysis.

  2026cites this paper
• Multifocal hepatocellular carcinoma in a noncirrhotic liver: A diagnostic pitfall mimicking cholangiocarcinoma and metastatic disease

  2026cites this paper
• Prospective Multicenter Evaluation of Hepatocellular Carcinoma Surveillance under American Association for the Study of Liver Diseases Version 2023 Guidance.

  2026cites this paper
• Non-thyroidal illness syndrome predicts poor prognosis in hepatocellular carcinoma patients treated with atezolizumab and bevacizumab

  2026cites this paper
• Patatin‐Like Phospholipase Domain Containing 3 I148M Variant Affects Hepatocellular Carcinoma Recurrence After Liver Resection

  2026cites this paper
• Comparative evaluation of regression and machine-learning models for hepatocellular carcinoma risk stratification across diverse aetiologies

  2026cites this paper
• Efficacy and Safety of Radiotherapy Combined with PD-1 Inhibitors and Targeted Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective, Real-World Multicenter Study.

  2026cites this paper
• The Effects of Lidocaine Patches on Post‐Radiofrequency Ablation Pain in Patients With Hepatocellular Carcinoma

  2026cites this paper
• Analysis of survival prognosis and influencing factors in patients with primary liver cancer after D-TACE: a retrospective cohort study

  2026cites this paper
• The Role of Aurora Kinase A in HBV-Associated Hepatocellular Carcinomas: A Molecular and Immunohistochemical Study

  2026cites this paper
• Comparison of diagnostic performance of GAAD, GALAD, and ASAP scores for detecting hepatocellular carcinoma in advanced liver fibrosis patients

  2026cites this paper
• Survival and Surrogate Biomarkers in Interventional Oncology Trials: Pitfalls, Challenges, and Future Directions.

  2026cites this paper
• Real-world Predictors of Early Mortality and Treatment Discontinuation in HCC Patients Treated with Atezolizumab–Bevacizumab

  2026cites this paper
• Muscle and fat matter: Automated CT-based body composition analysis predicts survival in Hepatocellular carcinoma patients undergoing radioembolization

  2026cites this paper
• A deep learning radiopathomic signature predicts recurrence risk of hepatocellular carcinoma after hepatectomy

  2026cites this paper
• Decoding IL4I1: The Core role of metabolism-driven immune regulation and new perspectives on disease targeting.

  2026cites this paper
• G-Quadruplex aptamer–nanoparticle platform for sensitive cytosensing of hepatocellular carcinoma

  2026cites this paper
• HCC risk stratification scores: insights from large multi-center national cohort study

  2026cites this paper
• Endovascular treatment of vascular complications following liver transplantation: A retrospective single-center study

  2026cites this paper
• Effects of contrast medium injection pressure on angiographic image quality

  2026cites this paper
• The Prognostic Nutritional Index (PNI) as a Biomarker for Predicting Survival in Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization and Lenvatinib, With or Without Programmed Death-1(PD-1) Inhibitors.

  2026cites this paper
• Advancing beyond survival rates: refining antiviral treatment evaluation in HBV/HCV-Related hepatocellular carcinoma post-resection.

  2026cites this paper
• Modular DNA nanosensors enable state-aware multiplexed single-molecule mass photometry in complex media

  2026cites this paper
• The bidirectional relationship between diabetes mellitus and liver disease: Mechanisms, clinical implications, and management strategies

  2026cites this paper
• A systematic review of MicroRNA (miRNA) biomarkers in the diagnosis and prognosis of hepatocellular carcinoma.

  2026cites this paper
• Development and validation of the APTNM staging system: Integration of serum biomarkers with TNM classification for enhanced prognostic stratification following hepatectomy for hepatocellular carcinoma.

  2026cites this paper
• An inertial-acoustofluidic platform for bioanalysis: concurrent, high-precision, high-throughput separation of cells and bacteria.

  2026cites this paper
• Roles of AFP, AFP-L3, DCP and GP73 in Diagnosis of Hepatocellular Carcinoma and Prediction of Recurrence in Patients

  2026cites this paper
• Establishment and Validation of a Nomogram Based on Inflammation-Immunity-Nutrition Biomarker Scores to Predict Postoperative Early Recurrence in Patients with Hepatocellular Carcinoma: A Multicenter Study

  2026cites this paper
• Survival Outcomes of Microwave Ablation Compared with Repeat Liver Resection in the Treatment of Recurrent Intrahepatic Cholangiocarcinoma.

  2026cites this paper
• A predictive model for optimal CT-guided thermal ablation margins in liver malignancies ≤3 cm: a retrospective cohort study.

  2026cites this paper
• Establishment of Patient-Derived Organoids from Hepatocellular Carcinoma: Preliminary Data on Yield, Histopathological Concordance, and Methodological Challenges

  2026cites this paper
• Clinical validation of a unified data-driven respiratory motion correction technique in 18F-FDG PET/CT imaging of upper abdominal lesions: a real-world study

  2026cites this paper
• Comparison of surgical resection and radiofrequency ablation for the treatment of small hepatocellular carcinoma (≤ 3 cm): an updated meta-analysis

  2026cites this paper
• Antiviral therapy is associated with achievement of statistical cure of patients undergoing liver resection for hepatocellular carcinoma: a retrospective study.

  2026cites this paper
• The impact of compliance with an enhanced recovery after surgery protocol on short-term outcomes in patients undergoing hepatectomy

  2026cites this paper
• Melanoma antigen genes A1 and A3 as predictors of treatment response and survival in HCV-associated hepatocellular carcinoma: a prospective study

  2026cites this paper
• Survival Benefit and Safety of Anatomic Resection in Cirrhotic Hepatocellular Carcinoma: Propensity‐Matched Analysis of 1699 Patients

  2026cites this paper
• Potential oncogene VPS72 in hepatocellular carcinoma: prognostic and immune infiltration implications

  2026cites this paper
• Real-World Analysis of Multidisciplinary Roles in the Management of Hepatocellular Carcinoma: The Mayo Clinic Experience

  2026cites this paper
• Q.Liver software for the planning of treatment of liver cancer via transarterial radioembolization with yttrium-90 resin microspheres based on single-photon emission computed tomography-computed tomography

  2026cites this paper
• Differentiation of focal liver lesions in contrast-enhanced ultrasound using a heuristic-guided hybrid machine-learning framework.

  2026cites this paper
• Post-Transplant Hepatocellular Carcinoma: Balancing Immunosuppression and Immune Checkpoint Inhibitors.

  2026influential citation
• Virtual Multi‐Phase Contrast Enhanced Liver MRI Using Deep Learning for Evaluating Hepatocellular Carcinoma

  2026cites this paper
• EP300 promotes hepatocellular carcinoma proliferation, migration and in vivo tumorigenicity revealed by integrated experimental and bioinformatic analyses.

  2026cites this paper
• Safety of Immune Checkpoint Inhibitors Prior to Liver Transplantation in Hepatocellular Carcinoma.

  2026cites this paper
• An interpretable machine learning model using routine clinical data for early recurrence prediction in hepatocellular carcinoma

  2026cites this paper
• Case Report: Percutaneous portal-central venous bypass: a novel salvage therapy for refractory variceal bleeding in TIPS-ineligible patients with portal vein tumor thrombus

  2026cites this paper
• The HIF-1α/LGR5/MAPK axis enhances hypoxia-induced metastatic potential in LGR5-positive hepatocellular carcinoma

  2026cites this paper
• Radiofrequency ablation versus surgical resection as first-line treatment for very early stage hepatocellular carcinoma: a systematic review with meta-analysis.

  2026cites this paper
• Safety and feasibility of liver maximum capacity assessment in patients undergoing transarterial chemoembolisation for hepatocellular carcinoma

  2026cites this paper
• Setting the Record Straight: Utility and Outcomes in Patients With HCV Related HCC

  2026cites this paper
• Decision Conflict Faced by First-Degree Relatives of Liver Cancer Patients in Liver Cancer Screening: A Cross-Sectional Study in China.

  2026cites this paper
• Itacitinib in advanced hepatocellular cancer following first line therapy

  2026cites this paper
• Clinically interpretable extracellular vesicle gene model for Non-Invasive liver cancer diagnosis.

  2026cites this paper
• FKBP10 as a prognostic biomarker and therapeutic target in hepatocellular carcinoma.

  2026cites this paper
• Augmenter of Liver Regeneration Enhances Hepatocellular Carcinoma Cell Growth Through COX-2-associated Signaling

  2026cites this paper
• Letter: Association Between Viral Replication Activity and Post‐Transplant Recurrence of HBV‐Related Hepatocellular Carcinoma

  2026cites this paper
• Integrated analysis of radiomics and RNA reveals the biological basis and therapeutic implications of aggressive hepatocellular carcinoma subtypes

  2026cites this paper
• ASAP score predicts early HCC recurrence after complete radiological response to locoregional treatments.

  2026cites this paper
• Clinical Applications of Immunogenomics in Hepatocellular Carcinoma.

  2026cites this paper
• Prognosis of liver transplantation and hepatectomy in patients with hepatocellular carcinoma meeting the Milan criteria: A systematic review and meta-analysis

  2026cites this paper
• A multicenter multinational retrospective study of the 1-year natural history of LI-RADS 3 observations in patients with cirrhosis.

  2026cites this paper
• Ultrasound and CT-guided 125I implantation combined with TACE therapy in the treatment of recurrent HCC after RFA.

  2026cites this paper
• Targeting PPP1R15B and ATF4 Axis in Hepatocellular Carcinoma: A Novel Strategy for Overcoming Lenvatinib-Tolerant Persister Cells Through GPX4-Mediated Ferroptosis Induction.

  2026cites this paper
• The Role of Galectin-3 in Liver Inflammation and Fibrosis

  2026cites this paper
• Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma with obstructive jaundice: A case report and review of literature

  2026cites this paper
• External validation of hepatocellular carcinoma recurrence model after surgery using the Royston-Altman approach.

  2026cites this paper
• Gadoxetic Acid-Enhanced Liver MRI for Differentiating Metabolic Predominance in Hepatocellular Carcinoma on Dual-Tracer PET/CT.

  2026cites this paper
• Tumour Burden Score as a Predictor of Extrahepatic Progression After Transarterial Chemoembolization for Hepatocellular Carcinoma: An Observational Multicenter Study.

  2026cites this paper
• Multibipolar radiofrequency vs single needle microwave ablation for the treatment of newly diagnosed hepatocellular carcinoma

  2026cites this paper
• Application of propensity score matching in prognostic analysis of portal hypertension in hepatocellular carcinoma patients

  2026cites this paper
• Artificial intelligence in hepatocellular carcinoma screening: applications and challenges

  2026cites this paper
• Liver Imaging Reporting and Data System: current status and future perspectives in the diagnosis of hepatocellular carcinoma

  2026cites this paper
• Dual-energy CT biomarkers for predicting the efficacy of TACE combined with lenvatinib and immune checkpoint inhibitors in unresectable HCC

  2026cites this paper
• Machine learning integrating MRI and clinical features predicts early recurrence of hepatocellular carcinoma after resection

  2026cites this paper
• GDF‐15 Levels in Cirrhosis Are Linked to Hepatic Fibrogenesis, Bacterial Translocation, and Worse Clinical Outcomes

  2026cites this paper
• ABO blood type has no effect on hepatocellular carcinoma recurrence after living donor liver transplantation in the Korean Organ Transplantation Registry study: a case-control study.

  2026cites this paper
• Photon-counting detector CT in oncology: a new era of cancer imaging

  2026cites this paper
• Thioredoxin-Binding protein 2 and apoptosis Signal-Regulating kinase 1: redox stress sensors and therapeutic targets in hepatocellular carcinoma

  2026cites this paper
• Utility of Serum Biomarkers in Addition to Ultrasound for Early Detection of Hepatocellular Carcinoma in High-Risk Patients: A Randomized Controlled Trial.

  2026cites this paper
• Serum N-glycan NA3Fb identified as a prognostic biomarker of poor outcome in HBV-related hepatocellular carcinoma

  2026cites this paper
• Metastatic Hepatocellular Carcinoma in a Non-Cirrhotic Liver without Viral Hepatitis: A Case Report and Literature Review

  2026cites this paper
• Assessment circulating micro-RNA-192 in Egyptian patients with non-viral liver cirrhosis and hepatocellular carcinoma

  2026cites this paper
• Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma.

  2026cites this paper
• Incidence and implications of abstinence-induced recompensation in alcohol-related cirrhosis.

  2026cites this paper
• HCC Is the Predominant Liver-Related Event in MASLD: 2-Step Non-Invasive Algorithms to Stratify Risk in Non-Cirrhotic Patients

  2026cites this paper
• Lenvatinib as Second-Line Regimen after Atezolizumab plus Bevacizumab Combination Therapy

  2026cites this paper
• Risk factors for hepatic failure after transarterial chemoembolization in patients with hepatocellular carcinoma: a systematic review and meta-analysis.

  2026cites this paper
• Integration of local and systemic immunotherapy: setting new standards in liver-confined hepatocellular carcinoma

  2026cites this paper
• Clarifying the decision rules and implementation boundaries for risk-based HCC surveillance in MASLD

  2026cites this paper
• Survival Prediction and Treatment Decisions in Hepatocellular Carcinoma: A Deep Learning-Based Radiomics Approach.

  2026cites this paper
• Minimally Invasive / Robotic Surgery for Hepatobiliary Cancer

  2026cites this paper
• Add-on PD-1 inhibitor with Peg-IFNα therapy favors functional cure of chronic hepatitis B patients

  2026cites this paper